Foghorn Therapeutics appoints Ryan Maynard as CFO
Source: SeekingAlpha
2026-02-23 07:27:07 ET
More on Foghorn Therapeutics
- Seeking Alpha’s Quant Rating on Foghorn Therapeutics
- Historical earnings data for Foghorn Therapeutics
- Financial information for Foghorn Therapeutics
Read the full article on Seeking Alpha
For further details see:
Foghorn Therapeutics appoints Ryan Maynard as CFO
Foghorn Therapeutics Inc.
NASDAQ: FHTX
FHTX Trading
2.37% G/L:
$5.62 Last:
92,595 Volume:
$5.45 Open:
FHTX Latest News
February 23, 2026 07:00:00 am
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
February 03, 2026 07:00:00 am
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
January 27, 2026 09:45:00 am
Hard-to-Treat Cancers: How 2026's Top Clinical Platforms Are Beating Industry Benchmarks
FHTX Stock Data
$308,770,038
29,565,014
4.18%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
